Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kyowa Kirin sells China plant to Dainippon Sumitomo

This article was originally published in Scrip

Executive Summary

Kyowa Hakko Kirin is to divest a wholly owned Chinese pharmaceutical manufacturing subsidiary to Dainippon Sumitomo Pharma(DSP). The former Kyowa Hakko packaging plant in Suzhou was completed in 2006 but had not begun commercial operations, and is being sold as part of restructuring following Kyowa's October 1st merger with Kirin. Financial terms were not disclosed but the subsidiary has net assets of around ¥1.5 billion ($15.5 million). DSP said it was looking to expand its local production capacity to meet growing demand in China, where it already has a marketing subsidiary and a packaging facility, also in Suzhou.

Kyowa Hakko Kirin is to divest a wholly owned Chinese pharmaceutical manufacturing subsidiary to Dainippon Sumitomo Pharma(DSP). The former Kyowa Hakko packaging plant in Suzhou was completed in 2006 but had not begun commercial operations, and is being sold as part of restructuring following Kyowa's October 1st merger with Kirin. Financial terms were not disclosed but the subsidiary has net assets of around ¥1.5 billion ($15.5 million). DSP said it was looking to expand its local production capacity to meet growing demand in China, where it already has a marketing subsidiary and a packaging facility, also in Suzhou.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC031714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel